Stephen Keith Carter

Stephen Keith Carter's AcademicInfluence.com Rankings

Chemistry

#2136

World Rank

#2998

Historical Rank

Organic Chemistry

#305

World Rank

#370

Historical Rank

chemistry Degrees

Download Badge

Chemistry

Why Is Stephen Keith Carter Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stephen Keith Carter's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Adriamycin. A new anticancer drug with significant clinical activity. (1974) (1051)
A clinical review of bleomycin—a new antineoplastic agent (1973) (823)
Cisplatin : current status and new developments (1980) (497)
Adriamycin-a review. (1975) (469)
Single Agents in Cancer Chemotherapy (1970) (329)
Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. (1973) (308)
The therapy of osteogenic sarcoma: Current status and thoughts for the future (1972) (271)
Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. (1987) (239)
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. (1983) (230)
Chemotherapy of cancer (1977) (198)
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. (1986) (192)
Integration of chemotherapy into combined modality treatment of solid tumors. 1. The overall strategy. (1974) (179)
Carboplatin: the clinical spectrum to date. (1985) (165)
1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review. (1972) (163)
Single and combination nonhormonal chemotherapy in breast cancer (1972) (155)
Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer (2004) (154)
Mitomycin C: Current status and new developments (1979) (145)
The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man (1970) (142)
Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. (1973) (142)
Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. (1975) (137)
The chemotherapy of urologic cancer (1975) (136)
Phase I clinical trials. (1977) (135)
Principles of cancer treatment (1982) (125)
The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. (1975) (124)
Clinical comparison of the nitrosoureas (1975) (120)
5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma. (1972) (108)
Editorial: Large-bowel cancer-The current status of treatment. (1976) (99)
Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast. (1976) (97)
A review of chemotherapy in gastric cancer (1974) (91)
Hexamethylmelamine. An evaluation of its role in the therapy of cancer (1976) (91)
The chemotherapy of prostatic adenocarcinoma. (1980) (90)
Integration of chemotherapy into combined modality treatment of solid tumorsII. Large bowel carcinoma (1974) (88)
The integration of chemotherapy into a combined modality approach to cancer therapy (1975) (88)
Bleomycin : current status and new developments (1978) (87)
Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. (1974) (83)
Perspectives on research in gynecologic oncology. Treatment protocols (1976) (80)
Anthracycline Antibiotics in Cancer Therapy (1982) (80)
Hexamethylmelamine--a new drug with activity in solid tumors. (1973) (78)
Antiestrogens in the treatment of breast cancer. (1976) (71)
Clinical strategy for the development of angiogenesis inhibitors. (2000) (66)
Review of CCNU in clinical cancer therapy (1974) (64)
Integration of chemotherapy into combined modality treatment of solid tumors: 1. The overall strategy (1974) (58)
The chemical therapy of breast cancer. (1974) (58)
The integration of chemotherapy into combined modality treatment of solid tumors. VIII. Cervical cancer. (1977) (56)
Calibrated phase II clinical trials in oncology. (1986) (54)
International Symposium on Adriamycin (1972) (46)
Glutamine antagonists in chemotherapy. (1970) (45)
Glioblastoma multiforme—A review of therapy (1974) (45)
Chromomycin A3, mithramycin, and olivomycin: antitumor antibiotics of related structure. (1975) (45)
Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn't? (1984) (45)
Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. (1984) (42)
Nafoxidine–‐an antiestrogen for the treatment of breast cancer (1976) (42)
Cisplatin — Past, Present and Future (1984) (41)
Patterns of failure in small cell carcinoma of the lung (1982) (41)
Plant products in cancer chemotherapy. (1976) (41)
Combination chemotherapy of advanced Hodgkin's disease. A review (1974) (38)
Methyl-CCNU inclinical cancer therapy. (1974) (38)
Clinical trials in cancer chemotherapy (1977) (35)
Single-agent therapy for Hodgkin's disease. (1973) (33)
Fundamentals of Cancer Chemotherapy (1986) (32)
A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine‐unresponsive metastatic prostatic carcinoma (1985) (31)
Cancer treatment today and its impact on drug development, with special emphasis on the phase II clinical trial. (1976) (31)
Gastric cancer: current status of treatment. (1977) (29)
Streptozotocin and metastatic insulinoma. (1971) (28)
Cyclophosphamide in solid tumors. (1975) (27)
Endometrial cancer: approach to development of effective chemotherapy. (1974) (26)
Combination radiation therapy and chemotherapy: A logical basis for their clinical use (1976) (26)
Adjuvant chemotherapy in lung cancer. Review and prospects (1977) (25)
New chemotherapeutic agents…bleomycin and adriamycin (1974) (25)
A comparison of the quality of participation of community affiliates and that of universities in the Northern California Oncology Group. (1983) (23)
NCI-EORTC symposium on new drugs in cancer therapy (2004) (23)
Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer. (2001) (22)
New cancer chemotherapeutic agents (1972) (21)
Cytosine arabinoside (NSC-63878)--clinical brochure. (1968) (20)
Fundamental and clinical studies of bleomycin (1976) (19)
Adjuvant chemotherapy of breast cancer. (1981) (19)
Carboplatin: future directions. (1985) (18)
An overview of the status of the nitrosoureas in other tumors. (1973) (18)
Sequential combination of bleomycin and mitomycin in advanced cervical cancer--an American experience: a Northern California Oncology Group study. (1982) (18)
Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole. (1983) (17)
Management of trials in the development of cancer chemotherapy. (1978) (16)
Some thoughts on experimental models and their clinical correlations. (1973) (16)
Nitrosoureas: 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962; BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC-79037; CCNU)--clinical brochure. (1968) (16)
The management of testicular cancer. (1983) (15)
Overview of early and investigational chemotherapeutic agents in solid tumors. (1976) (15)
Clinical trials in cancer chemotherapy. (1977) (15)
4′-Demethyl-epipodophyllotoxin-β-d-thenylidene glucoside (VM-26)—A brief review (1973) (14)
Phase II clinical trials. (1977) (14)
The Cancer Therapy Evaluation Program of the National Cancer Institute. (1981) (13)
Osteogenic sarcoma treatment overview and some comments on interpretation of clinical trial data. (1978) (13)
The dilemma of adjuvant chemotherapy for osteogenic sarcoma. (1980) (13)
Perspectives on research in gynecologic oncology. (1976) (12)
IMMUNOTHERAPY OF CANCER IN MAN: CURRENT STATUS AND PROSPECTUS (1976) (12)
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck. (1975) (11)
Treatment of primary breast cancer. (1985) (11)
Chapter 1 – BLEOMYCIN: MORE THAN A DECADE LATER (1985) (11)
Joint lethal effects of actinomycin D and radiation in mice. (1970) (11)
Investigational drugs under study by the United States National Cancer Institute. (1976) (11)
Carboplatin: the clinical evaluation strategy. (1985) (11)
The clinical evaluation of analogs — III. Anthracyclines (2004) (11)
Clinical trials in patients with cancer. (1982) (10)
The nitrosoureas--thoughts for the future. (1976) (10)
Chemotherapy and genitourinary oncology (1978) (10)
Current therapies in osteosarcoma. (1975) (10)
MANAGEMENT OF LOCALLY ADVANCED AND DISSEMINATED BREAST CANCER (1981) (10)
Chemotherapy of cancer, 3rd ed (1987) (9)
Experimental design considerations in clinically combining radiation and drugs. (1979) (9)
The Development and Clinical Testing of New Anticancer Drugs at the National Cancer Institute — Example cis-Platinum (II) Diamminedichloride (NSC 119 875) (1974) (9)
On screening procedures. (1970) (9)
Cancer chemotherapy as it approaches middle age (2004) (9)
Chapter 17 – POCC VERSUS POCC/VAM THERAPY FOR SMALL-CELL ANAPLASTIC (OAT CELL) LUNG CANCER (1981) (9)
The clinical evaluation of analogues (2004) (8)
Screening at the National Cancer Institute. (1977) (8)
Experimental models and their clinical correlations. (1977) (8)
Predictors of response and their clinical evaluation (2004) (8)
Some thoughts on resistance to cancer chemotherapy. (1984) (8)
Historical background of the National Cancer Institute's drug development thrust. (1977) (8)
Chemotherapy of disseminated gastric cancer. A joint effort of the Northern California oncology group and the Japanese gastric cancer chemotherapy group (1983) (8)
Planning combined therapy--the interaction of experimental and clinical studies. (1974) (8)
The Integration of Adriamycin into Combined Therapy Approaches (1975) (8)
Prednisone and Prednisolone (1970) (7)
New Drugs in Cancer Chemotherapy (1981) (6)
Diagnostic accuracies of clinical studies in patients with small cell carcinoma of the lung. (1983) (6)
Adjuvant chemotherapy for operable breast cancer with positive axillary nodes (1977) (6)
New drugs on the horizon in bronchogenic carcinoma (1972) (6)
Phase III trial of irradiation plus chemotherapy for patients with hepatic metastases and hepatoma: experience of the Northern California Oncology Group. (1988) (5)
Current status of new agents. (1972) (5)
Improving the therapeutic index of systemic therapy with special emphasis on cisplatin and carboplatin. (1987) (5)
Chemotherapy in advanced breast cancer. (1978) (5)
The clinical evaluation of analogues (2004) (5)
5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196)--clinical brochure. (1968) (5)
A perspective on adjuvant chemotherapy of testicular cancer (1979) (5)
Current investigational drugs of interest in the Chemotherapy Program of the National Cancer Institute. (1977) (5)
Chapter 35 – DESIGN OF CLINICAL TRIALS WITH NITROSOUREA (1981) (5)
The current status of clinical immunotherapy as viewed at the 1976 AACR-ASCO meetings (1976) (4)
Clinical research and drug development of antivirals in HIV: an industry perspective. (1995) (4)
Surgery plus adjuvant chemotherapy —A review of therapeutic implications (2004) (4)
Pulmonary complications of cancer chemotherapy. (1973) (3)
Mitomycin C (NSC-26980)--clinical brochure. (1968) (3)
Adjuvant chemotherapy in breast cancer: Critique and perspectives (2004) (3)
The search for therapeutic cell controls by the chemotherapy program of the National Cancer Institute. (1972) (3)
Clinical research and experimental design (1979) (3)
The interpretation of trials: Combined hormonal therapy and chemotherapy in disseminated breast cancer (2005) (3)
Chemotherapy of Cancer of the Prostate (1982) (3)
Clinical trials and primary breast cancer the therapeutic implications (1984) (3)
The Anthracyclines--A Historical Perspective (1982) (3)
Current status of American studies with bleomycin. (1976) (3)
The analysis of adjuvant trials. (1978) (3)
Perspectives on Combined Modality Treatment with Emphasis on Radiation Therapy and Chemotherapy (1979) (3)
The clinical evaluation of analogues, IV. Nitrosoureas. (1980) (3)
Adjuvant Chemotherapy of Cancer (1986) (3)
Interim report on a phase III study of bleomycin and methotrexate with radiotherapy in the treatment of inoperable head and neck cancer (1980) (3)
An overview of the 1978 international meeting on comparative therapeutic trials. (1978) (3)
The california breast cancer law and government‐mandated patient education (1982) (3)
The dilemma of estrogen receptors and the response rate to cytotoxic chemotherapy. A problem of comparability analysis. (1979) (3)
Immunotherapy of cancer in man. (1976) (3)
The potential lack of comparability between interim and final results of cancer clinical trials (1982) (3)
New drugs under clinical evaluation in the United States (2004) (2)
The dilemma of local control of breast cancer. (1982) (2)
Immunotherapy in the strategy of cancer treatment (1976) (2)
C.R.O.S. Conference on Combined Modalities Chemotherapy/Radiotherapy (1979) (2)
Antitumor antibiotics--thoughts for the future. (1978) (2)
Clinical considerations in the design of clinical trials. (1980) (2)
Azotomycin (NSC-56654)--clinical brochure. (1968) (2)
Second tumors complicating cancer chemotherapy. (1978) (2)
The Strategy of Cancer Treatment (1987) (2)
Dibromodulcitol (NSC-104800)--clinical brochure. (1968) (2)
The carcinogenic potential of cytotoxic chemotherapy and its implications for therapeutic decision-making (2004) (2)
The current status of immunotherapy for large bowel cancer (1976) (2)
The old versus the new combinations: drugs and irradiation for head and neck cancer. (1980) (2)
Current protocol approaches in large bowel cancer. (1976) (2)
Anticancer drug development--a challenge for industry and government. (1984) (2)
Biologic response-modifying agents: What is an appropriate phase I–II strategy? (1980) (2)
Developing new drugs for ovarian cancer: A challenging task in a changing reality (2004) (2)
Prophylaxis and “Total Therapy” of Meningeal Leukemia (1972) (2)
Selection bias in clinical trials. (1986) (2)
Review : Adjuvant use of cytotoxic chemotherapy to destroy micrometastasis in breast cancer after local control therapy—current status (2004) (2)
4'-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside (VM-26)--a brief review. (1973) (1)
Anthracycline antibiotics in cancer therapy : proceedings of the International Symposium on Anthracycline Antibiotics in Cancer Therapy, New York, New York, 16-18 September 1981 (1982) (1)
Importance of controlling the regional draining lymph nodes in breast cancer. (1978) (1)
Rationale and Design of a Trial to Evaluate the Cardiotoxocity of Weekly Schedules of Adriamycin, with Endomyocardial Biopsy used as an End Point (1982) (1)
Introduction to methodology of clinical trials in the varieties of acute leukemia; defining the numerator and denominator in leukemic trials. (1973) (1)
Preliminary results of a United States-Japan cooperative trial in patients with disseminated gastric cancer. (1981) (1)
New Anticancer Drugs (2011) (1)
Introduction of U.S.-Japan Joint Meeting on Phase I and II Clinical Trials (1980) (1)
Phase III studies and the strategy for integrating chemotherapy into a combined modality approach. (1977) (1)
Treatment of Hodgkin's disease. (1973) (1)
Pelvic irradiation plus adriamycin and cyclophosphamide in selected patients with epithelial ovarian carcinoma: a phase II study of the Northern California Oncology Group. (1984) (1)
DESIGN OF CLINICAL TRIALS WITH CISPLATIN ANALOGS (1980) (1)
Methods of development of new anticancer drugs : U.S.A.-U.S.S.R. monograph (1977) (1)
Chemotherapy and genitourinary oncology. I. Bladder cancer. (1978) (1)
Perusing the ASCO abstracts with a focus on interferons in malignant melanoma and renal cell carcinoma (2004) (1)
The clinical evaluation of BRM agents. (1980) (1)
2,2'-(9,10-anthrylenedimethylene)bis[2-thiopseudourea], dihydrochloride, dihydrate (NSC-56054)--clinical brochure. (1968) (1)
Current therapy approaches of the division of cancer treatment with emphasis on pancreatic carcinoma (1974) (1)
A Chemotherapeutic Perspective on Clinical Trials with Corynebacterium parvum (1975) (1)
Adjuvant chemotherapy for breast cancer. Implications of clinical trials. (1985) (1)
Methodology of data reporting in advanced breast cancer trials (2004) (1)
Radiotherapy in cooperative clinical trials: Northern California Oncology Group (NCOG) method. (1980) (1)
Future directions in the therapy for large bowel cancer. (1982) (1)
Commentary: Combination chemotherapy of nonseminomatous testicular cancer (2004) (1)
Effective participation in cooperative clinical trials by an independent community organization: An NCOG Model (1983) (1)
Conference on combined modalities: chemotherapy/radiotherapy. Hilton Head Island, South Carolina, November 15-18, 1978. (1979) (1)
Cancer treatment and cancer control: the dynamic interaction between clinical research and community oncology. (1981) (1)
Clinical chemotherapy: its correlation with experimental models. (1980) (1)
Adjuvant chemotherapy of cancer. A review of its current status. (1986) (1)
Cancer Chemotherapy: New Developments and Changing Concepts (1980) (1)
Anthracycline analogs: re-assessments and prospects. (1979) (1)
Second opinion: The United States public and the demise of health care reform, 1993--1994 (2003) (0)
Childhood cancer: triumph over tragedy. Introduction. (1981) (0)
Clinical trials (2004) (0)
Cancer chemotherapy: What drugs are available. (1976) (0)
The linear array. (1977) (0)
Adjuvant chemotherapy. (1985) (0)
Neoplastic Heterogeneity and Clinical Chemotherapy (1989) (0)
How valid is disease-free survival as an endpoint in adjutant trials (1980) (0)
Microsoft Word - OCL405BF (2009) (0)
Medical oncology. (1977) (0)
Chemotherapy of lung cancer. (1982) (0)
Oat cell carcinoma. A multimodality comparison. Radiotherapy plus sequential chemotherapy vs. radiotherapy plus alternating chemotherapy (1980) (0)
Central Nervous System Involvement by Burkitt’s Lymphoma (1972) (0)
Proceedings: Anticancer drug development programs: a comparison of approaches in the United States, the Soviet Union, Japan, and Western Europe. (1974) (0)
Clinical research and community oncology. (1983) (0)
A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts (2004) (0)
Combined modality approach to oat cell carcinoma (1981) (0)
The strategy of cancer treatment: testicular carcinoma. (1977) (0)
Characteristics of Meningeal Leukemia (1972) (0)
Chemotherapy for radiation oncologists (1984) (0)
Some thoughts on surgical adjuvant studies in lung cancer. (1973) (0)
Combination Radiotherapy and Chemotherapy in Meningeal Leukemia (1972) (0)
Pancreatic Islet Cell Carcinoma (2020) (0)
Some thoughts on experimental screening. (1975) (0)
The analog potential in cancer chemotherapy in the United States and Japan. (1981) (0)
What you can do for your patients with breast cancer. (1978) (0)
Adjuvant Chemotherapy of Osteogenic Sarcoma and Surgical Resection of Pulmonary Metastases (1984) (0)
Advances in cancer chemotherapy : proceedings of the 8th international symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, 1977 (1978) (0)
Corynebacterium parvum Outlook and Future (1975) (0)
The current status of adjuvant chemotherapy in breast cancer. (1981) (0)
Application of Large Animal Toxicology to the Qualitative and Quantitative Predication of Drug Toxicity in Man (1974) (0)
The strategy of cancer treatment: introduction. (1977) (0)
Cancer chemotherapy 1973—present: A personal perspective (2005) (0)
Bronchogenic carcinoma: new drugs available for study. (1973) (0)
Cancer chemotherapy. (1980) (0)
Editorial: clinical research and community involvement. (1978) (0)
Chemotherapy for metastatic disease. (1983) (0)
Adriamycin--friend and foe. (1977) (0)
The chemotherapy of head and neck cancer. (1977) (0)
Treating breast carcinoma. (1976) (0)
Systemic Therapy for Meningeal Leukemia (1972) (0)
Antlestrogens in the treatment of breast cancer (1976) (0)
Porfiromycin (NSC-56410)--clinical brochure. (1968) (0)
An Overview of Therapy of Acute Leukemia (1972) (0)
The Chemotherapy of Micrometastases — An Overview of Current Status (1980) (0)
Concluding remarks on malignant lymphomas. (1978) (0)
Cooperative clinical trials and community outreach: the conceptual approach in Northern California. (1978) (0)
The Contribution of Clinical Trials to the Study of Breast Cancer (1989) (0)
5-Fluorouracil as adjuvant chemotherapy for large bowel cancer is it appropriate for routine community use? (2004) (0)
New cytotoxic drugs for breast cancer and their clinical evaluation. (1980) (0)
Short Summary of the Informal Meeting Preceeding the Adriamycin Symposium (1972) (0)
Tumor Heterogeneity and Empirical Clinical Cancer Chemotherapy: Current Status and Future Prospects (1986) (0)
Adjuvant chemotherapy of solid tumors (1987) (0)
Population-based study of small-cell lung cancer. (1985) (0)
Quality of Life in Cancer and AIDS (1997) (0)

This paper list is powered by the following services:

Stephen Keith Carter's Academic­Influence.com Rankings

Why Is Stephen Keith Carter Influential?

Stephen Keith Carter's Published Works

Published Works

Stephen Keith Carter's AcademicInfluence.com Rankings